Global Information
회사소개 | 문의 | 비교리스트

대사형 글루탐산 수용체 2(mGluR2, GRM2, GPRC1B, MGLUR2) : 파이프라인 리뷰

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 363567
페이지 정보 영문 58 Pages
가격
US $ 3,500 ₩ 4,337,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,675,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 13,013,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


대사형 글루탐산 수용체 2(mGluR2, GRM2, GPRC1B, MGLUR2) : 파이프라인 리뷰 Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 58 Pages

세계 각국에서의 대사형 글루탐산 수용체 2(mGluR2, GRM2, GPRC1B, MGLUR2) 치료제 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

  • 서론
    • 분석 범위
  • 대사형 글루탐산 수용체 2(mGluR2, GRM2, GPRC1B, MGLUR2) 개요
  • 치료제 개발 상황
    • 임상시험 단계별
    • 치료 분야별
    • 증상별
  • 파이프라인 제품 개요
    • 후기 단계 제품
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 각 대학 및 연구기관에서 개발중인 치료제
  • 치료제 평가
    • 단독치료 제품/병용 제품별
    • 작용기서별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • Addex Therapeutics Ltd
    • Domain Therapeutics SA
    • Eli Lilly and Company
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Taisho Pharmaceutical Holdings Co., Ltd.
  • 약제 개요
  • 개발이 휴지 상태인 제품
  • 개발이 중지된 제품
  • 주목해야 할 최신 동향 및 프레스 릴리스
  • 부록

도표

KSM 16.08.04

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Addex Therapeutics Ltd, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Camino Pharma LLC, H2 2019
  • Pipeline by Denovo Biopharma LLC, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by Johnson & Johnson, H2 2019
  • Pipeline by Mediti Pharma Inc, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Dormant Products, H2 2019 (Contd..2), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019

Summary

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization.

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 8 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Treatment Resistant Depression, Depression, Drug Addiction, Psychosis, Anxiety Disorders, Dementia, Dementia Associated With Alzheimer's Disease, Epilepsy, Ischemia, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Post-Traumatic Stress Disorder (PTSD) and Stroke.

The latest report Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
  • The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Bristol-Myers Squibb Co
  • Camino Pharma LLC
  • Denovo Biopharma LLC
  • Eli Lilly and Co
  • Johnson & Johnson
  • Mediti Pharma Inc
  • Merck & Co Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles
  • ADX-92639 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMT-133218 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-40411813 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-5515 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3020371 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-341495 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MGS-0274 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MP-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pomaglumetad methionil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SBP-0069330 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize MGLUR2 for Cardiovascular and Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products
  • Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
  • Sep 04, 2018: Addex's selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
  • Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
  • Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
  • Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death
  • Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
  • Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
  • Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
  • Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
  • Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms
  • Aug 29, 2012: Lilly Stops Phase III Development Of Pomaglumetad Methionil For Treatment Of Schizophrenia Based On Efficacy Results
  • Jul 11, 2012: Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint Of Clinical Study
  • Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms
  • Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia
  • Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer's Disease Model
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q